ReviewExpert review of clinical pharmacology2015
Pharmacologic and clinical evaluation of posaconazole.
Review in Expert review of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Antifungal Agents' Trends of Utilization, Spending, and Prices in the US Medicaid Programs: 2009-2023.Antibiotics (Basel, Switzerland) · 2025Article
- Real-world correlation between therapeutic drug monitoring and clinical outcomes of the antifungal drug posaconazole: a single-center retrospective cohort study.Frontiers in pharmacology · 2025Article
- Antifungal Susceptibility and Genotypic Analysis ofInfection and drug resistance · 2024Article
- Single-Dose Crossover Comparative Bioavailability Study of Two Different Posaconazole 100 mg Gastro-Resistant Tablets Under Fasted and Fed Conditions in Healthy Volunteers.Infectious diseases & clinical microbiology · 2023Article
- Hot Melt Extruded Posaconazole-Based Amorphous Solid Dispersions-The Effect of Different Types of Polymers.Pharmaceutics · 2023Article
- Post-COVID-19 Fungal Infection in the Aged Population.Vaccines · 2023Review
- Formation and Characterisation of Posaconazole Hydrate Form.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Adverse Events Associated with Universal versus Targeted Antifungal Prophylaxis among Lung Transplant Recipients-A Nationwide Cohort Study 2010-2019.Microorganisms · 2022Article
- Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients.Frontiers in pharmacology · 2022Article
- The Impact of Gelatin on the Pharmaceutical Characteristics of Fucoidan Microspheres with Posaconazole.Materials (Basel, Switzerland) · 2021Article
- Piperazine based antimicrobial polymers: a review.RSC advances · 2021Review
- Posaconazole-Induced Apparent Mineralocorticoid Excess.Kidney international reports · 2020Article
- Deciphering the Relationship Between the Trough Concentration of Posaconazole and Its Efficacy and Safety in Chinese Patients With Hematological Disorders.Frontiers in pharmacology · 2020Article
- Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study.Frontiers in microbiology · 2020Article
- Antifungal Drugs Influence Neutrophil Effector Functions.Antimicrobial agents and chemotherapy · 2019Article
- Serum Levels of Crushed Posaconazole Delayed-Release Tablets.Antimicrobial agents and chemotherapy · 2019Article
- The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors.Frontiers in microbiology · 2019Review
- A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.European journal of drug metabolism and pharmacokinetics · 2018Review
- Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis.Antimicrobial agents and chemotherapy · 2018Article
- Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.Scientific reports · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. There is evidence of efficacy in the treatment and prevention of rarer, more difficult-to-treat fungal infections. Posaconazole oral suspension solution has shown limitations with respect to fasting state absorption, elevated gastrointestinal pH and increased motility. The newly approved delayed-release oral tablet and intravenous solution formulations provide an attractive treatment option by reducing interpatient variability and providing flexibility in critically ill patients. On the basis of clinical experience and further clinical studies, posaconazole was found to be a valuable pharmaceutical agent for the treatment of life-threatening fungal infections. This review will examine the development history of posaconazole and highlight the most recent advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.